BioSpace News Archive

Astellas Pharma Inc. announced the following changes to its management structure effective April 1, 2024.

Veru Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its Phase 2b clinical study to evaluate enobosarm.

Processa Pharmaceuticals, Inc. announces it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Market and that the matter is now closed.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced that it has received authorization from the Uzbekistan Ethics Committee to open the clinical trial site for its proof-of-concept human clinical study evaluating the use of transvascular ablation for the treatment of pancreatic cancer pain.

Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

4D Molecular Therapeutics, Inc. announced that it priced an upsized underwritten public offering of 6,586,015 shares of its common stock at a public offering price of $29.50 per share and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 3,583,476 shares of common stock at a public offering price of $29.4999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (“ASCO”) Plenary Series Session on February 6, 2024.

Mithra, a company dedicated to women’s health, provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.

Orexo AB, announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

AlzeCure Pharma AB announced that an abstract on preclinical data with its lead drug candidate NeuroRestore ACD856 has been accepted for a poster presentation at AD/PD 2024, which will be held in Lisbon on March 5-9.